The nights are getting shorter and the green shoots of spring are emerging – and it’s an exciting time for Optimum Strategic Communications as it launches Optimum TV! Our associate director and former national newspaper journalist Stephen Adams will be presenting regular YouTube episodes showcasing our clients’ amazing work. Heidelberg grabs orphan designation Heidelberg […]
Ladenburg, Germany, 27 March 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for the treatment of multiple myeloma to its lead candidate HDP-101. Heidelberg Pharma is investigating the […]
First efficacy data from the clinical trial with HDP-101 in multiple myeloma Expansion of the ADC technology platform to include further payloads New Management Board team Successful financing activities; sales revenue and other income above plan Conference call to be held on 25 March 2024 at 03:00 pm CET/ 10:00 am EDT Ladenburg, Germany, 25 […]
Ladenburg, Germany, 19 March 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced the formal closing of the royalty purchase agreement with HealthCare Royalty (HCRx) for Zircaix®, signed earlier this month. Under the terms of the agreement, Heidelberg Pharma has received an upfront, non-refundable cash payment of […]
Optimum’s clients continued to gain momentum in March, starting things off on Monday with a substantial financing agreement for Heidelberg Pharma, with HealthCare Royalty for up to $115 million. On Wednesday, Heidelberg followed this with the announcement that it is to present first efficacy data from a Phase 1 clinical trial with ATAC candidate HDP-101. […]
